BST Position Update – October 30, 2015

| October 30, 2015

BST Position Update

. . . . Verastem (NASD: $VSTM) – Sell 

Verastem stock has tanked after announcing they have halted their drug study. The company has stopped a mid-stage study of VS-6063, Verastem’s leading mesothelioma cancer treatment candidate, after studies showed the treatment was not effective enough to warrant any further studies.

Let’s cut our losses and try to recover some capital…

Sell VSTM.

. . . . Arena Pharmaceuticals (NASDAQ: $ARNA) – Hold 

Arena Pharmaceuticals, Inc. (ARNA) announced yesterday the initiation of patient dosing in a Phase1 clinical study for the drug ADP371. APD371 is being tested to determine its effectiveness against treating pain without the potential for dependence or abuse.

Even though the current price of the stock is $1.69, which is down from our buy price of $4.01, let’s hold onto this one and see how this new trial turns out.

Hold ARNA.

. . . . Cerus (NASDAQ: $CERS) – Buy

Big news for this pharmaceutical company… The clinical study that was testing INTERCEPT, a blood system for platelets and plasma, is now FDA-approved in the US. The Community Blood Center of the Carolinas (CBCC), which provides over 12,000 platelet and 22,000 plasma units annually to 27 regional hospitals has just signed a three-year purchase agreement for the INTERCEPT blood system.

The stock is currently trading at $4.82 and my buy up to price is $6.60 so there is still time to get in on the action.

Buy CERS now.

Action To Take

  • Sell VSTM
  • Hold ARNA
  • Buy CERS

Category: BST Update

About the Author ()

Comments are closed.